Business in the Burbs

Regeneron receives $20 million after patient enrolled in study

July

Regeneron Pharmaceuticals Inc., a biotech company based in Eastview, said that it has received a $20 million payment after enrolling the first patient in a study that looks at the effectiveness of its its VEGF Trap-Eye as a potential treatment for central retinal vein occlusion, a leading cause of blindness.

Regeneron received the payment as part of an agreement with Bayer HealthCare AG, its partner in developing VEGF Trap-Eye as a treatment for various eye diseases. The latest testing program includes patients from multiple countries participating in two one-year studies.

This entry was posted on Thursday, July 23rd, 2009 at 4:09 pm by Jay Loomis. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.